# Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

> **NCT05788081** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Olivia Newton-John Cancer Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Follicular Lymphoma Stage II
- Follicular Lymphoma Stage III
- Follicular Lymphoma Stage IV

## Interventions

- **DRUG:** golcadomide
- **DRUG:** Nivolumab 10 MG/ML
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05788081
- **Lead sponsor:** Olivia Newton-John Cancer Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05788081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05788081, "Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT05788081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*